BioLife Solutions Inc (NASDAQ:BLFS) Director Joseph C. Schick sold 3,287 shares of the business’s stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $21.00, for a total transaction of $69,027.00. Following the transaction, the director now directly owns 8,588 shares in the company, valued at $180,348. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
BLFS traded down $0.08 during midday trading on Thursday, hitting $20.90. 2,409 shares of the company traded hands, compared to its average volume of 134,520. The company has a quick ratio of 7.71, a current ratio of 9.42 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $398.62 million, a PE ratio of 148.61 and a beta of 1.43. The company’s 50-day moving average is $19.36 and its 200 day moving average is $18.01. BioLife Solutions Inc has a 52 week low of $9.15 and a 52 week high of $22.44.
BioLife Solutions (NASDAQ:BLFS) last posted its earnings results on Thursday, August 8th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.02 by $0.02. The business had revenue of $6.70 million for the quarter, compared to analysts’ expectations of $6.59 million. BioLife Solutions had a net margin of 14.60% and a return on equity of 8.65%. On average, sell-side analysts predict that BioLife Solutions Inc will post 0.08 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently bought and sold shares of BLFS. JPMorgan Chase & Co. bought a new position in BioLife Solutions during the 2nd quarter valued at about $30,000. Signaturefd LLC purchased a new stake in BioLife Solutions in the 1st quarter worth approximately $161,000. Alpine Woods Capital Investors LLC purchased a new stake in BioLife Solutions in the 2nd quarter worth approximately $170,000. Morgan Stanley increased its holdings in BioLife Solutions by 17.5% in the 2nd quarter. Morgan Stanley now owns 11,506 shares of the medical equipment provider’s stock worth $195,000 after acquiring an additional 1,713 shares in the last quarter. Finally, Menta Capital LLC purchased a new stake in BioLife Solutions in the 2nd quarter worth approximately $202,000. Institutional investors and hedge funds own 48.44% of the company’s stock.
About BioLife Solutions
BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.
Read More: How to invest in a bear market
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.